| Frequency and outcomes of gastrostomy insertion in a longitudinal cohort study of atypical parkinsonism C Kobylecki, V Chelban, YY Goh, E Michou, R Fumi, M Theilmann Jensen, ... European Journal of Neurology, e16258, 2024 | | 2024 |
| Network connectivity and structural correlates of survival in progressive supranuclear palsy and corticobasal syndrome DJ Whiteside, D Street, AG Murley, PS Jones, M Malpetti, BCP Ghosh, ... Human Brain Mapping 44 (11), 4239-4255, 2023 | 3 | 2023 |
| Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials D Street, E Jabbari, A Costantini, PS Jones, N Holland, T Rittman, ... Brain 146 (8), 3232-3242, 2023 | 6 | 2023 |
| Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis G Bensimon, PN Leigh, T Tree, C Garlanda, M Locati, J Kirby, P Shaw, ... US Patent App. 17/904,734, 2023 | | 2023 |
| Comparison of King’s clinical staging in multinational amyotrophic lateral sclerosis cohorts R Balendra, AR Jones, A Al Khleifat, T Chiwera, P Wicks, CA Young, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 24 (1-2), 71-81, 2023 | 3 | 2023 |
| Profiling non-coding RNA expression in cerebrospinal fluid of amyotrophic lateral sclerosis patients G Joilin, E Gray, AG Thompson, K Talbot, PN Leigh, SF Newbury, ... Annals of Medicine 54 (1), 3068-3077, 2022 | 9 | 2022 |
| Neurofilament light levels predict clinical progression and death in multiple system atrophy V Chelban, E Nikram, A Perez-Soriano, C Wilke, A Foubert-Samier, ... Brain 145 (12), 4398-4408, 2022 | 19 | 2022 |
| Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy FA Simoes, G Joilin, O Peters, LS Schneider, J Priller, EJ Spruth, I Vogt, ... International journal of molecular sciences 23 (23), 14554, 2022 | 3 | 2022 |
| Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021 … T Dam, AL Boxer, LI Golbe, GU Hoglinger, HR Morris, I Litvan, AE Lang, ... NATURE MEDICINE, 2022 | | 2022 |
| Clinical trials in pediatric ALS: a TRICALS feasibility study T Kliest, RPA Van Eijk, A Al-Chalabi, A Albanese, PM Andersen, ... Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 23 (7-8), 481-488, 2022 | 3 | 2022 |
| A man with Erb’s disease S Leddy, F Jaffer, M Lipnicka-Khan, PN Leigh Journal of Neurology, Neurosurgery & Psychiatry 93 (6), A100-A100, 2022 | | 2022 |
| Altered network stability in progressive supranuclear palsy DJ Whiteside, PS Jones, BCP Ghosh, I Coyle-Gilchrist, A Gerhard, MT Hu, ... Neurobiology of Aging 107, 109-117, 2021 | 10 | 2021 |
| Automated Midbrain-Pons Ratio using Artificial Intelligence Differentiates PSP from other Atypical Parkinsonian Disorders M Peres, G Leroy, A Gerhard, M Hu, J Klein, P Leigh, A Church, D Burn, ... MOVEMENT DISORDERS 36, S254-S255, 2021 | | 2021 |
| Facial onset sensory and motor neuronopathy: new cases, cognitive changes, and pathophysiology EMJ De Boer, AW Barritt, M Elamin, SJ Anderson, R Broad, A Nisbet, ... Neurology: Clinical Practice 11 (2), 147-157, 2021 | 22 | 2021 |
| Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis R Dewan, R Chia, J Ding, RA Hickman, TD Stein, Y Abramzon, S Ahmed, ... Neuron 109 (3), 448-460. e4, 2021 | 68 | 2021 |
| Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study E Jabbari, S Koga, RR Valentino, RH Reynolds, R Ferrari, MMX Tan, ... The Lancet Neurology 20 (2), 107-116, 2021 | 86 | 2021 |
| Full title: Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2 I Giovannelli, N Bayatti, A Brown, D Wang, M Mickunas, W Camu, ... | | 2021 |
| Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2 I Giovannelli, N Bayatti, A Brown, D Wang, M Mickunas, W Camu, ... Brain Communications 3 (3), fcab141, 2021 | 20 | 2021 |
| Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial W Camu, M Mickunas, JL Veyrune, C Payan, C Garlanda, M Locati, ... EBioMedicine 59, 2020 | 50 | 2020 |
| Reply to: Early white matter changes on diffusion tensor imaging in amyotrophic lateral sclerosis MC Gabel, RJ Broad, AL Young, S Abrahams, ME Bastin, LH Goldstein, ... Annals of Clinical and Translational Neurology 7 (7), 1266, 2020 | | 2020 |
ammar al-chalabiProfessor of Neurology and Complex Disease Genetics, King's College London在 kcl.ac.uk 的电子邮件经过验证
